Resources from the same session
4O - Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
Presenter: James Chih-Hsin Yang
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 1
Resources:
Webcast
2O - SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi
Presenter: Myung-Ju Ahn
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
3O - Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts
Presenter: Nicolas Girard
Session: Proffered Paper session 1
Resources:
Abstract
1O - Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD
Presenter: Xiuning Le
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 2O, 3O and 1O
Presenter: Pei Li Stephanie Saw
Session: Proffered Paper session 1
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 1
Resources:
Webcast